These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19659563)

  • 1. Musical obsession: repeated auditory imagery of a cell phone ring tone.
    Mendhekar DN; Andrade C
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):591-2. PubMed ID: 19659563
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions.
    Goodman WK; Ward H; Kablinger A; Murphy T
    J Clin Psychiatry; 1997; 58 Suppl 5():32-49. PubMed ID: 9184625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obsessive-compulsive disorder.
    Veale D; Roberts A
    BMJ; 2014 Apr; 348():g2183. PubMed ID: 24709802
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical features in two cases with musical obsessions who successfully responded to clomipramine.
    Matsui T; Matsunaga H; Ohya K; Iwasaki Y; Koshimune K; Miyata A; Kiriike N
    Psychiatry Clin Neurosci; 2003 Feb; 57(1):47-51. PubMed ID: 12519454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Musical obsessions: a comprehensive review of neglected clinical phenomena.
    Taylor S; McKay D; Miguel EC; De Mathis MA; Andrade C; Ahuja N; Sookman D; Kwon JS; Huh MJ; Riemann BC; Cottraux J; O'Connor K; Hale LR; Abramowitz JS; Fontenelle LF; Storch EA
    J Anxiety Disord; 2014 Aug; 28(6):580-9. PubMed ID: 24997394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic management of obsessive-compulsive disorder.
    Jackson CW; Morton WA; Lydiard RB
    South Med J; 1994 Mar; 87(3):310-21. PubMed ID: 8134850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obsessive-compulsive spectrum disorders.
    Hollander E; Wong CM
    J Clin Psychiatry; 1995; 56 Suppl 4():3-6; discussion 53-5. PubMed ID: 7713863
    [No Abstract]   [Full Text] [Related]  

  • 9. Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder.
    Barr LC; Goodman WK; Anand A; McDougle CJ; Price LH
    Am J Psychiatry; 1997 Sep; 154(9):1293-5. PubMed ID: 9286191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?
    Todorov C; Freeston MH; Borgeat F
    Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
    Dell'Osso B; Allen A; Hollander E
    Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs).
    Ravizza L; Barzega G; Bellino S; Bogetto F; Maina G
    Psychopharmacol Bull; 1996; 32(1):167-73. PubMed ID: 8927668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Obsessive-compulsive disorder, frontostriatal system and the effect of the serotonergic system].
    Baving L; Schmidt MH
    Z Kinder Jugendpsychiatr Psychother; 2000 Feb; 28(1):35-44. PubMed ID: 10746297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of clomipramine in obsessive-compulsive disorder.
    Howland RH
    Anxiety; 1996; 2(1):56-7. PubMed ID: 9160602
    [No Abstract]   [Full Text] [Related]  

  • 17. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
    Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB
    Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.
    Greist JH; Jefferson JW; Kobak KA; Katzelnick DJ; Serlin RC
    Arch Gen Psychiatry; 1995 Jan; 52(1):53-60. PubMed ID: 7811162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective treatment with low-dose fluvoxamine for obsessive-compulsive disorder after neurosurgery: a case report.
    Kunitake Y; Hurukawa Y; Yamada S
    Clin Neuropharmacol; 2009; 32(6):344-5. PubMed ID: 19952875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in platelet markers of obsessive-compulsive patients during a double-blind trial of fluvoxamine versus clomipramine.
    Marazziti D; Pfanner C; Palego L; Gemignani A; Milanfranchi A; Ravagli S; Lensi P; Presta S; Cassano GB
    Pharmacopsychiatry; 1997 Nov; 30(6):245-9. PubMed ID: 9442546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.